Molecule Details
| InChIKey | PMQUGSPFUBGJCZ-CHOKWEPUSA-N |
|---|---|
| Canonical SMILES | Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 7.59 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB19200 |
|---|---|
| Drug Name | Luvixasertib |
| CAS Number | 1610759-22-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer). |
Cross-references: BindingDB: 50512456 CHEMBL4469414 ChemSpider: 60600040
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P33981 | TTK | Dual specificity protein kinase TTK | inhibitor | targets |